Company: KROS
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001104659-25-099512
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 7.01
Chunk 3
---
Item 7.01 Regulation FD Disclosure.

On October 15, 2025,
the Company issued a press release announcing several corporate updates, including, among other matters, (i) the execution of the
Repurchase Agreements and the related resignations of Tomer Kariv and Ran Nussbaum from the Company’s board of directors and all
committees thereof, and (ii) the Company’s intention to commence a tender offer. A copy of the press release is attached as
Exhibit 99.1 and incorporated herein by reference.

The information in this Item
7.01 to Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”) or otherwise subject
to the liabilities of that section. The information contained in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K
is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set
forth by specific reference in such filing.

Item 8.01 Other Events.